secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001193125-24-056209
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus prices $100M public offering of common stock and pre-funded warrants at $32/share
--------------------------------------------------------------------------------

- Offering consists of 2,812,500 shares common stock at $32.00/share and pre-funded warrants for 312,500 shares at $31.9999 each.
- Underwriters granted 30-day option to purchase up to 468,750 additional shares at $32.00 less discounts.
- Gross proceeds ~$100M; net proceeds expected ~$93.7M after discounts and expenses.
- Offering expected to close March 5, 2024, subject to customary conditions.
- Goldman Sachs, BofA, Guggenheim, and Oppenheimer are joint book-running managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000119312524056209/0001193125-24-056209-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000119312524056209/d759306d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-056209

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer